In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI),
gadopentetate dimeglumine (Magnevist®), became available for clinical use. Since then, a …

Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI
methodology has not been standardized, hindering its utilization for response assessment in …

Sampling restrictions have hindered the comprehensive study of invasive non-enhancing
(NE) high-grade glioma (HGG) cell populations driving tumor progression. Here, we present …

Object It has been demonstrated that an extensive resection (total or subtotal) may
significantly increase the overall survival in patients with WHO Grade II gliomas (low-grade …

Purpose: To retrospectively determine whether relative cerebral blood volume (CBV)
measurements can be used to predict clinical outcome in patients with high-grade gliomas …

Abstract High-grade glioma (HGG), and particularly Glioblastoma (GBM), can exhibit
pronounced intratumoral heterogeneity that confounds clinical diagnosis and management …

Purpose: To investigate whether estimates of relative cerebral blood volume (rCBV) in brain
tumors, obtained by using dynamic susceptibility-weighted contrast material–enhanced …

The two most common methods for measuring perfusion with MRI are based on dynamic
susceptibility contrast (DSC) and arterial spin labeling (ASL). Although clinical experience to …

BACKGROUND AND PURPOSE: Atypical and malignant meningiomas are uncommon
tumors with aggressive behavior and higher mortality, morbidity, and recurrence compared …

Dynamic susceptibility contrast magnetic resonance imaging (DSC‐MRI) is used to track the
first pass of an exogenous, paramagnetic, nondiffusible contrast agent through brain tissue …